Selected research
Industry Research
Liposomes Industry Research Report 2026
Market perspective
The global Liposomes market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Liposomes is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Liposomes is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Liposomes is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Liposomes include CSPC, Fudan-Zhangjiang, Gilead Sciences, Kingond Pharm, Luye Pharma, Pacira, Sigma-Tau Group, Spectrum Pharmaceuticals and Teva Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Liposomes market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liposomes Market by Company
CSPC
Fudan-Zhangjiang
Gilead Sciences
Kingond Pharm
Luye Pharma
Pacira
Sigma-Tau Group
Spectrum Pharmaceuticals
Teva Pharmaceutical
Novartis
Johnson & Johnson
Shanghai New Asia
Sun Pharmaceutical
Liposomes Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Liposomes Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
Liposomes Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liposomes manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liposomes by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liposomes in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Others
Applications
- Fungal Infection Therapy
- Cancer & Tumor Therapy
- Others
Companies covered
- CSPC
- Fudan-Zhangjiang
- Gilead Sciences
- Kingond Pharm
- Luye Pharma
- Pacira
- Sigma-Tau Group
- Spectrum Pharmaceuticals
- Teva Pharmaceutical
- Novartis
- Johnson & Johnson
- Shanghai New Asia
- Sun Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Liposomes Market Size (2021-2032)
- 2.2.2 Global Liposomes Sales (2021-2032)
- 2.2.3 Global Liposomes Market Average Price (2021-2032)
- 2.3 Liposomes by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Liposomal Doxorubicin
- 2.3.3 Liposomal Amphoteracin B
- 2.3.4 Liposomal Paclitaxel
- 2.3.5 Others
- 2.4 Liposomes by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Fungal Infection Therapy
- 2.4.3 Cancer & Tumor Therapy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Liposomes Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Liposomes Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Liposomes Revenue of Manufacturers (2021-2026)
- 3.4 Global Liposomes Average Price by Manufacturers (2021-2026)
- 3.5 Global Liposomes Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Liposomes, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Liposomes, Product Type & Application
- 3.8 Global Manufacturers of Liposomes, Established Date
- 3.9 Global Liposomes Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSPC
- 4.1.1 CSPC Company Information
- 4.1.2 CSPC Business Overview
- 4.1.3 CSPC Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSPC Liposomes Product Portfolio
- 4.1.5 CSPC Recent Developments
- 4.2 Fudan-Zhangjiang
- 4.2.1 Fudan-Zhangjiang Company Information
- 4.2.2 Fudan-Zhangjiang Business Overview
- 4.2.3 Fudan-Zhangjiang Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Fudan-Zhangjiang Liposomes Product Portfolio
- 4.2.5 Fudan-Zhangjiang Recent Developments
- 4.3 Gilead Sciences
- 4.3.1 Gilead Sciences Company Information
- 4.3.2 Gilead Sciences Business Overview
- 4.3.3 Gilead Sciences Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gilead Sciences Liposomes Product Portfolio
- 4.3.5 Gilead Sciences Recent Developments
- 4.4 Kingond Pharm
- 4.4.1 Kingond Pharm Company Information
- 4.4.2 Kingond Pharm Business Overview
- 4.4.3 Kingond Pharm Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kingond Pharm Liposomes Product Portfolio
- 4.4.5 Kingond Pharm Recent Developments
- 4.5 Luye Pharma
- 4.5.1 Luye Pharma Company Information
- 4.5.2 Luye Pharma Business Overview
- 4.5.3 Luye Pharma Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Luye Pharma Liposomes Product Portfolio
- 4.5.5 Luye Pharma Recent Developments
- 4.6 Pacira
- 4.6.1 Pacira Company Information
- 4.6.2 Pacira Business Overview
- 4.6.3 Pacira Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pacira Liposomes Product Portfolio
- 4.6.5 Pacira Recent Developments
- 4.7 Sigma-Tau Group
- 4.7.1 Sigma-Tau Group Company Information
- 4.7.2 Sigma-Tau Group Business Overview
- 4.7.3 Sigma-Tau Group Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sigma-Tau Group Liposomes Product Portfolio
- 4.7.5 Sigma-Tau Group Recent Developments
- 4.8 Spectrum Pharmaceuticals
- 4.8.1 Spectrum Pharmaceuticals Company Information
- 4.8.2 Spectrum Pharmaceuticals Business Overview
- 4.8.3 Spectrum Pharmaceuticals Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Spectrum Pharmaceuticals Liposomes Product Portfolio
- 4.8.5 Spectrum Pharmaceuticals Recent Developments
- 4.9 Teva Pharmaceutical
- 4.9.1 Teva Pharmaceutical Company Information
- 4.9.2 Teva Pharmaceutical Business Overview
- 4.9.3 Teva Pharmaceutical Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Teva Pharmaceutical Liposomes Product Portfolio
- 4.9.5 Teva Pharmaceutical Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis Liposomes Product Portfolio
- 4.10.5 Novartis Recent Developments
- 4.11 Johnson & Johnson
- 4.11.1 Johnson & Johnson Company Information
- 4.11.2 Johnson & Johnson Business Overview
- 4.11.3 Johnson & Johnson Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Johnson & Johnson Liposomes Product Portfolio
- 4.11.5 Johnson & Johnson Recent Developments
- 4.12 Shanghai New Asia
- 4.12.1 Shanghai New Asia Company Information
- 4.12.2 Shanghai New Asia Business Overview
- 4.12.3 Shanghai New Asia Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Shanghai New Asia Liposomes Product Portfolio
- 4.12.5 Shanghai New Asia Recent Developments
- 4.13 Sun Pharmaceutical
- 4.13.1 Sun Pharmaceutical Company Information
- 4.13.2 Sun Pharmaceutical Business Overview
- 4.13.3 Sun Pharmaceutical Liposomes Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Sun Pharmaceutical Liposomes Product Portfolio
- 4.13.5 Sun Pharmaceutical Recent Developments
5 Global Liposomes Market Scenario by Region
- 5.1 Global Liposomes Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Liposomes Sales by Region: 2021-2032
- 5.2.1 Global Liposomes Sales by Region: 2021-2026
- 5.2.2 Global Liposomes Sales by Region: 2027-2032
- 5.3 Global Liposomes Revenue by Region: 2021-2032
- 5.3.1 Global Liposomes Revenue by Region: 2021-2026
- 5.3.2 Global Liposomes Revenue by Region: 2027-2032
- 5.4 North America Liposomes Market Facts & Figures by Country
- 5.4.1 North America Liposomes Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Liposomes Sales by Country (2021-2032)
- 5.4.3 North America Liposomes Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Liposomes Market Facts & Figures by Country
- 5.5.1 Europe Liposomes Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Liposomes Sales by Country (2021-2032)
- 5.5.3 Europe Liposomes Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Liposomes Market Facts & Figures by Country
- 5.6.1 Asia Pacific Liposomes Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Liposomes Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Liposomes Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Liposomes Market Facts & Figures by Country
- 5.7.1 South America Liposomes Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Liposomes Sales by Country (2021-2032)
- 5.7.3 South America Liposomes Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Liposomes Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Liposomes Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Liposomes Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Liposomes Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Liposomes Sales by Type (2021-2032)
- 6.1.1 Global Liposomes Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Liposomes Sales Market Share by Type (2021-2032)
- 6.2 Global Liposomes Revenue by Type (2021-2032)
- 6.2.1 Global Liposomes Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Liposomes Revenue Market Share by Type (2021-2032)
- 6.3 Global Liposomes Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Liposomes Sales by Application (2021-2032)
- 7.1.1 Global Liposomes Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Liposomes Sales Market Share by Application (2021-2032)
- 7.2 Global Liposomes Revenue by Application (2021-2032)
- 7.2.1 Global Liposomes Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Liposomes Revenue Market Share by Application (2021-2032)
- 7.3 Global Liposomes Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Liposomes Value Chain Analysis
- 8.1.1 Liposomes Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Liposomes Production Mode & Process
- 8.2 Liposomes Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Liposomes Distributors
- 8.2.3 Liposomes Customers
9 Global Liposomes Analyzing Market Dynamics
- 9.1 Liposomes Industry Trends
- 9.2 Liposomes Industry Drivers
- 9.3 Liposomes Industry Opportunities and Challenges
- 9.4 Liposomes Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst